Year: 2023
Type: article
Abstract: HIV therapeutic targets: Basic virology to the discovery of antiretroviral drugs Do we need new antiretroviral drugs to treat HIV infection, and if so, what are the promising targets? Dr Eric O. Freed, Director of the HIV Dynamics and Replication Program at the National Cancer Institute in Frederick, Maryland, discusses these questions. The HIV replication cycle (1) (see figure) presents numerous potential therapeutic targets, but only a few have been successfully exploited. HIV-1 infection begins when the viral envelope glycoprotein (known as Env) binds to its primary receptor (CD4) and coreceptors on the surface of a target cell, leading to a fusion between the lipid bilayer of the virus particle and the plasma membrane of the cell, allowing the viral core – which contains the viral RNA genome and key viral enzymes – to gain access to the target cell cytoplasm.
Source: Open Access Government
Author: Eric O. Freed
Institution: National Cancer Institute
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4365450407